Inhibikase Therapeutics, Inc. (IKT) financial statements and ratios from SEC XBRL: revenue $0.00 (TTM), revenue growth -100.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $0.00 |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | -67.5% |
| FCF Growth (YoY) | 5.8% |
| Price / Book | 2.18 |
| FCF Yield | -20.7% |
| Sector P/E (Healthcare) | 21.7 |
IKT overview · IKT earnings · IKT KPIs · IKT investor relations · IKT ownership · IKT peers · IKT filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.